ISSUE: There have been significant advances in technology and machine learning methods to support systematic reviews. Indeed, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for reporting systematic reviews has recognized the application of automation tools within their recently updated 2020 updated guideline. However, many health technology assessment (HTA) agencies have not yet issued formal guidance around the application and use of technology and machine-learning applications to support systematic reviews in submissions and technology appraisals. In the absence of such guidance, it is unclear whether use of emerging technologies and machine learning applications to support systematic reviews will be accepted by global HTA bodies. There is an urgent need to explore this issue from a multi-stakeholder perspective.

OVERVIEW: This panel will debate whether technology and machine-learning enabled systematic reviews can meet the evidence requirements of global HTA bodies. Dr. Chris Cameron will moderate the panel and provide an overview of the current landscape of technology and machine-learning applications, as well as HTA requirements on systematic reviews to support global HTA submissions. He will also pose key questions for the panelists to debate, including:

• What are the opportunities with leveraging technology and machine-learning enabled systematic reviews for HTA submissions?
• What are the challenges with leveraging technology and machine-learning enabled systematic reviews for HTA submissions?
• Why might technology and machine-learning enabled systematic reviews be acceptable for publications, but not be considered well suited for HTA submissions?
• Which technology and machine-learning methods are most acceptable from an HTA perspective?

International experts will each describe their unique perspective from technology/ML developer, HTA and academic perspective on technology and machine-learning enabled systematic reviews in support of HTA submissions. Target stakeholders include HTA agencies, academics, patient advocacy organizations, and pharma/biotech manufacturers.